title: Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction.
abstract: OBJECTIVE
  In the Intracoronary Stenting and Antithrombotic Regimen-2 trial (ISAR-2), we sought to investigate the effect of abciximab on angiographic and clinical restenosis after stenting following acute myocardial infarction (AMI). We also intended to assess the impact of abciximab on clinical outcome in this setting.
  
  
  BACKGROUND
  It is unclear whether abciximab reduces neointima formation after stenting. Such an effect may be particularly prominent in thrombus-containing lesions.
  
  
  METHODS
  Patients undergoing stenting within 48 h after onset of AMI were randomly assigned to receive either standard-dose heparin or abciximab plus reduced-dose heparin. Of 401 patients randomized, 366 without 30-day adverse events were eligible for six-month angiographic follow-up. Scheduled angiography was performed in 80% of these patients.
  
  
  RESULTS
  By 30 days, the composite clinical end point of death, reinfarction, and target lesion revascularization (TLR) was reached in 5.0% of the abciximab group and in 10.5% of the control group (p = 0.038). At one year, absolute reduction in the composite clinical end point by abciximab was still 5.7% but had lost its statistical significance. Our primary end point, late lumen loss, was 1.26+/-0.85 mm with abciximab and 1.21+/-0.74 mm with standard heparin (p = 0.61), and binary angiographic restenosis rates were 31.1% and 30.6%, respectively (p = 0.92).
  
  
  CONCLUSIONS
  In patients undergoing stenting following AMI, abciximab exerted beneficial effects by substantially reducing the 30-day rate of major adverse cardiac events. During one-year follow-up, there was no additional benefit from a reduction in TLR nor did abciximab reduce angiographic restenosis.
authors.affiliation: Deutsches Herzzentrum und 1. Medizinische Klinik der Technischen Universität München, Munich, Germany. neumann@med1.med.tu-muenchen.de
authors.forename: F J
authors.initials: FJ
authors.lastname: Neumann
authors.forename: A
authors.initials: A
authors.lastname: Kastrati
authors.forename: C
authors.initials: C
authors.lastname: Schmitt
authors.forename: R
authors.initials: R
authors.lastname: Blasini
authors.forename: M
authors.initials: M
authors.lastname: Hadamitzky
authors.forename: J
authors.initials: J
authors.lastname: Mehilli
authors.forename: M
authors.initials: M
authors.lastname: Gawaz
authors.forename: M
authors.initials: M
authors.lastname: Schleef
authors.forename: M
authors.initials: M
authors.lastname: Seyfarth
authors.forename: J
authors.initials: J
authors.lastname: Dirschinger
authors.forename: A
authors.initials: A
authors.lastname: Schömig
mesh_terms: D000077284:Abciximab; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D015331:Cohort Studies; D017023:Coronary Angiography; D005260:Female; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D012008:Recurrence; D015607:Stents; D015996:Survival Rate
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D006493:Heparin; D000077284:Abciximab